

Implementation of a Clinical Nutrition Clinic for Cancer Patients. Will It Improve Health Outcomes?

Raslan M², Shehata EM², Sara AR² and Sabri NA^{1*}

¹Department of Clinical Pharmacy, Faculty of Pharmacy- Ain Shams University, Cairo, Egypt

²Drug Research Centre, Cairo, Egypt

*Corresponding author:

Nagwa Ali Sabri,
Department of Clinical Pharmacy, Faculty of
Pharmacy- Ain Shams University, Cairo, Egypt,
Tel: +201223411984;
E-mail: nagwa.sabri@pharma.asu.edu.eg/
nagwa.sabri@yahoo.com

Received: 02 Aug 2022

Accepted: 11 Aug 2022

Published: 16 Aug 2022

J Short Name: COO

Copyright:

©2022 Sabri NA, This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citation:

Sabri NA. Implementation of a Clinical Nutrition Clinic for Cancer Patients. Will It Improve Health Outcomes?. Clin Onco. 2022; 6(9): 1-7

1. Abstract

1.1. Background: Cancer exerts a massive burden on society in both developed and developing countries. Cancer is becoming more common as the population grows and ages, as well as the incidence of identified risk factors rises.

1.2. Aim: The review aimed to establish a clinic for cancer patients in which a balanced diet will be adjusted to them based on investigations of the relationship between food product consumption, dietary intake, and the occurrence of side effects, tumour development, and associated illness in cancer patients undergoing chemotherapy.

1.3. Methods: Clinical nutrition clinic structure was mentioned with significance of each individual in the clinic team. Furthermore, a literature search was done to collect different evidences supporting the review aim.

1.4. Discussion: Several studies indicated that dietary changes have a promising positive effect on chemotherapy side effects like GIT side effects, tumour incidence and growth, and so improving patients' quality of life.

1.5. Conclusion: The collected data showed that dietary intake with specific food products have a significant impact on the health status of cancer patients including the side effects of chemotherapy, radiation and co morbidities. A dietary approach focused on the exclusion or limited intake of specific food products, as well as diet improvement, might minimize chemotherapy-induced problems and hence should be considered in clinical practice.

2. Introduction

According to dietary guidelines for cancer patients, it is advised to analyze nutrient intakes, changes in body weight and BMI since cancer diagnosis, nutritional assessment, and repeat review depending on clinical stability [1]. The energy requirements and biology of the tumour, the body's reaction to the existence of the tumour, and the influence of therapies all contribute to increased caloric requirements in cancer patients [2].

Chemotherapy treatments are associated with a variety of nutrition-related symptoms such as loss of appetite, nausea, vomiting, and taste changes, all of which interfere with patients' ability to eat and enjoy meals, resulting in impaired nutritional intake, nutritional status deterioration, and decreased quality of life. And so, drug treatment to promote appetite may result in higher food intake, weight gain, and better quality of life [3].

Furthermore, DNA methylation is a frequent epigenetic alteration that affects gene expression, and abnormal DNA methylation patterns are considered a cancer hallmark. Micronutrients, bioactive chemicals, and mycotoxins all have the ability to influence DNA methylation patterns and so contribute to cancer prevention and onset [4].

In one-carbon metabolism and other DNA methylation processes, micronutrients like as choline, folate, betaine, and methionine function as cofactors or methyl donors. Curcumin, epigallocatechin-3-gallate, genistein, quercetin, resveratrol, and sulforaphane are dietary bioactive compounds that reactivate essential tumour

suppressor genes by correcting aberrant DNA methylation patterns, and hence have shown potential against various cancers. On the other hand, fungus-infested agricultural foods are a source of potent mycotoxins that promote carcinogenesis [4].

It is observed that cancer cells are excessive users of metabolic fuels, such as glucose, amino acids, and fats. Dietary interventions could lead to improved outcomes with little or no additional toxicity. Indeed, some data show that diet interventions could potentially reduce chemotherapy side effects. Unfortunately, the vast majority of the discourse has been based on opinion and anecdotal evidence, and a paucity of scientifically validated diet interventions

can be offered to cancer patients [5].

Frequent investigations are done to address the effect of dietary changes and nutrients on cancer patients' quality of life, incidence of side effects, emerging diseases, and tumor growth and / or inhibition.

The current review will explore the different investigations done in this issue and what are the influence of dietary changes on improvement cancer patient total quality of life. Furthermore, it will investigate the establishment of a clinical nutrition clinic for cancer patients to provide them nutritional and therapeutic guidance.




Figure 1: Global number and proportion of cancer cases attributable to alcohol consumption according to cancer type. [34]

Table 1: Preclinical studies examining the role of fasting on cancer outcome

| Cancer (cell line) | Animal model | Route | Fasting scheme | Effect of fasting alone | Effect of fasting with treatment | Reference |
|--------------------------|--------------------------------------|--------------|-----------------------------------|-------------------------|--|-----------|
| Immunocompetent | | | | | | |
| Breast (67NR and 4T1) | 14-week-old BALB/c | Orthotopic | alternate day feeding | Slowed tumor growth | Synergy with irradiation | 24 |
| Breast (4T1) | 12-week-old BALB/c female | Subcutaneous | Two 48- to 60-hour fasting cycles | Slowed tumor growth | Synergy with cyclophosphamide | 25 |
| Melanoma (B16) | 12-week-old C57BL/6 male and female | Subcutaneous | Two 48- to 60-hour fasting cycles | Slowed tumor growth | Synergy with doxorubicin | 25 |
| Colorectal (CT26) | 6-week-old female BALB/c | Subcutaneous | Two 48-hour fasting cycles | Slowed tumor growth | Synergy with oxaliplatin | 26 |
| Immunocompromised | | | | | | |
| Breast (H3122) | 6- to 8-week-old athymic BALB/c mice | Subcutaneous | Three 48-hour fasting cycles | Slowed tumor growth | Synergy with crizotinib (tyrosine kinase inhibitor) | 27 |
| Colorectal (HCT116) | 6- to 8-week-old athymic BALB/c mice | Subcutaneous | Three 48-hour fasting cycles | Slowed tumor growth | Synergy with regorafenib (tyrosine kinase inhibitor) | 27 |
| Glioma (GL26) | 7-week-old nude mice | Subcutaneous | One 48- to 60-hour fasting cycle | Slowed tumor growth | Synergy with doxorubicin | 24 |

Table 2: Preclinical trials of ketogenic diets on cancer outcome

| Cancer (cell line) | Animal model | Route | Diet scheme | Effect of fasting alone | Effect of fasting with treatment | Reference |
|--------------------------------|---------------------------|--------------|--|---|--|-----------|
| Breast (4T1) | BALB/C | Subcutaneous | 70% of ad libitum of diet containing 2% carbohydrates and 93.4% fat calories | Reduced tumor growth | Enhanced antitumor effect of metformin | 29 |
| Lung (NCI-H292 and A549 cells) | Female athymic-nu/nu mice | Subcutaneous | ad libitum 1.6% carbohydrates and 90% fat calories | No effect of ketogenic diet alone on tumor volume or survival | Enhanced tumor response and survival with Irradiation and/or carboplatin | 30 |
| Glioma (GL261) | Female albino C57BL/6 | Orthotopic | ad libitum 3% carbohydrates and 72% fat calories | Prolonged survival | Synergistic with whole brain irradiation | 31 |

Table 3: Foods, Dietary Supplements, and Cancer Drug Interactions [32].

| Herbal/Dietary Supplement | Anticancer Therapy | Effect |
|--|--------------------|---|
| St. John's wort | Irinotecan | Increased activity of CYP3A4 and decreased AUC of active metabolite SN38 |
| St. John's wort | Imatinib | Increased clearance and decreased AUC of imatinib |
| St. John's wort | Methotrexate | Increased AUC and C_{max} of methotrexate |
| St. John's wort | Docetaxel | Increased clearance and decreased AUC of docetaxel |
| St. John's wort | Ixabepilone | May decrease plasma concentrations of ixabepilone |
| Green tea | Sunitinib | Decreased drug absorption and bioavailability of sunitinib |
| Green tea | Palbociclib | Decreased oral bioavailability of palbociclib |
| Green tea extract | Erlotinib | Decreased AUC and oral bioavailability of erlotinib |
| Green tea extract | Lapatinib | Decreased AUC and oral bioavailability of lapatinib |
| Epigallocatechin gallate (an antioxidant component of green tea) | Tamoxifen | Increased bioavailability of tamoxifen |
| Epigallocatechin gallate | Irinotecan | Increased plasma concentration of irinotecan and decreased hepatobiliary excretion of drug and its metabolite SN-38 |
| Green tea and Epigallocatechin gallate | Fluorouracil | Increased AUC and C_{max} of fluorouracil |
| Grapefruit | Imatinib | May increase plasma levels of imatinib by inhibiting CYP3A4 |
| Grapefruit | Etoposide | Decreased AUC and bioavailability of etoposide |
| Grapefruit | Sunitinib | Increased bioavailability of sunitinib |
| Grapefruit | Nilotinib | Increased AUC and C_{max} of nilotinib |
| Vitamin A | Imatinib | Increased bioavailability of imatinib |
| Vitamin E | Imatinib | Increased bioavailability of imatinib |
| Vitamin D3 | Imatinib | Increased bioavailability of imatinib |
| Vitamin C | Imatinib | Decreased bioavailability of imatinib |
| Scutellaria baicalensis | Docetaxel | Increased AUC of drug and exposure to both drug and herb |

3. Materials and Methods

The clinical nutrition clinic role is to optimize the dietary intake on individual level for each cancer patient. This will provide patients with a better quality of life and minimal adverse effects. A specialized team and tools are required to provide the nutritional service.

3.1. The suggested clinic team, their roles and the required instruments will be as follows:

3.1.1. Dietitians or Nutritionists: Their primary function is to provide nutritional care expertise [6], malnutrition assessment, improve cancer care and optimize quality of life [7].

3.1.2. Oncologist: Participate in clinical and translational research to advance innovation and novel therapeutics, contribute to cancer diagnosis, prevention, and research. Also, oncologist provide a complete and systematic approach to treatment and care, while assuring the use of cancer medications that is evidence-based, safe, and cost-effective [8].

clinicsofoncology.com

3.1.3. Clinical Pharmacist: Adopting scientifically reliable knowledge and guidance on safe, reasonable use of chemotherapy, optimizing therapeutic efficacy, minimizing adverse effects, and resolving unclear/compliant issues [9].

Besides, the pharmacists have a variety of responsibilities in parenteral nutrition treatment, including: assessing patients' nutritional needs; designing, compounding, dispensing, and quality management of parenteral nutrition formulations; monitoring patients' response to parenteral nutrition therapy, educating patients, caregivers, and other health care professionals about nutrition support [10].

3.1.4. Nurses: Nurses are in a good position to provide screening, referral, coordination, physical exercise consulting, nutritional advice, direct nutritional nursing, psychological support, symptom control, and hospice care [11].

3.1.5. Computer system: A clinical Nutritional Information Sys-

tem satisfies dietitians' demands by improving the quality of nutritional therapies by providing precise calculations and cross-referencing for information about patients' conditions, while also reducing processing time, as opposed to handwritten paperwork. Furthermore, the CNIS assists dietitians in statistically analyzing each patient's particular nutritional demands in order to achieve nutritional improvement [12].

3.1.6. Nutrition registry: To overcome the significant gap in the knowledge available to assist the activity of hospital-based dietitians and to address the question of how the majority of patients might avoid acquiring protein-energy malnutrition [13].

4. Discussion

A retrospective observational study in Italy found that clinical nutrition is associated with positive survival outcomes in metastatic patients with gastrointestinal, respiratory, and genitourinary cancer; besides, it was associated with significant improvement in survival in malnourished metastatic patients with gastrointestinal and genitourinary cancer. Furthermore, early administration of clinical nutrition was associated with improvement in survival in non-metastatic patients with gastrointestinal cancer [14].

Recent studies have shown that patients who were given nutritional support showed reduced in-hospital mortality, and they were discharged from a post-acute care facility less frequently [15].

A clinical study showed that clinical pharmacist interventions were associated with a significant decrease in the toxicity grades of breast cancer, such as anaemia, where the percentage of grade 2 patients decreased from 17 percent to 1.7 percent; additionally, 5 percent of grade 4 nausea/vomiting, which decreased to zero percent after pharmacist intervention [16].

4.1. Correlation between diet and incidence of chemotherapy' side effects

A clinical trial involving 56 women undergoing chemotherapy for ovarian cancer was done to analyze dietary intake and the relationship between the consumption of certain food products and the prevalence of gastrointestinal problems. According to the findings, 23 percent and 32 percent of patients never suffered nausea or constipation, respectively, while 43 percent and 45 percent never experienced vomiting or diarrhea. Oils caused nausea, chocolate and chocolate goods caused constipation, while dairy products, stone fruit, and apple caused diarrhea. Vomiting was shown to have significant inverse associations with calories, fat, protein, carbs, B vitamins, vitamin D, phosphorus, and zinc consumption [17].

Dietary changes are recommended in addition to pharmaceutical treatment for chemotherapy-induced diarrhea. These include avoiding hot meals, caffeine, alcohol, and fruit juices, as well as high osmolar dietary supplements, vegetables, particularly cruciferous vegetables, as well as lactose-containing goods, high fibre, and high fat foods [17].

Constipation is also one of the most common complaints experienced by cancer patients. It was shown that these constipation patients report changing stool shape following meal and beverage consumption more frequently than healthy people. Furthermore, chocolate was the most commonly cited and considered to promote constipation among them [17].

Chemotherapy-induced gastrointestinal (GI) side effects in breast cancer patients are prevalent but poorly understood, and they may be addressed with dietary management. A total of 150 patients with breast cancer having chemotherapy were randomly allocated to either the intervention group ($n = 73$) or the control group ($n = 67$) for 10 weeks after their three rounds of chemotherapy. The severity of GI side effects, which included reflux disorder, anorexia, nausea, constipation, and diarrhea, was considerably reduced in the third session of chemotherapy compared to the first session, which included dietary intervention and nutritional education [18].

Clinical studies recommended avoiding acidic and caffeinated foods and drinks such as citrus fruits, fatty and fried foods, garlic, onions, mint, spicy foods, tomato-based foods, carbonated drinks, lying down right after every meal, and consuming small amounts of food very slowly to prevent the occurrence of reflux in breast cancer patients undergoing chemotherapy [19].

Nutrition recommendations for reducing diarrhoea in breast cancer patients undergoing chemotherapy included eating frequent small meals, drinking clear liquids (water, weak herbal tea, apple juice, clear broth, frozen pops), eating foods high in pectin, a water soluble fibre found in apple sauce, bananas, and yoghurt, and eating foods high in potassium and sodium [19].

Nutrition education in breast cancer patients undergoing chemotherapy included the following criteria to consider: eating frequent small meals, consuming foods at room temperature rather than in a warm place, rinsing their mouth before and after each meal, sitting up or lying down with their head raised for at least an hour after each consumption, and avoiding spicy, fried, sugary, or highly aromatic foods and in contrast, having bland, soft or easy-to-digest foods especially in their chemotherapy time, having liquids with ice chips or frozen juice chips, having deep breaths and relax after their therapies, drinking clear and cold liquids such as ginger ale, apple juice, broth, and tea, sucking on hard candy with pleasant smells such as lemon drops or mints which helps them to get rid of bad tastes, if they developed a general dislike of red meat and meat broths during treatment, they would better consume other protein sources, such as fish, chicken, beans, and nuts [20].

Health care professionals should keep in mind that cancer patients are immunocompromised and when infected with COVID-19 they may present with fever and respiratory symptoms due to a subsequent opportunistic bacterial infection. Even pneumonitis can arise with the use of some cytotoxic chemotherapies [21]. That is why health care providers should take a special care regarding patients' health state and nutrition.

Mass vaccination and immunization will be important in preventing the spread of Covid-19 [22]. This is an important for cancer patients to avoid potential complications and additional comorbidities from covid-19 infection. Furthermore, as we mentioned before that these patients are immunocompromised, and so mortality rates may increase.

5. Cancer Incidence and Tumor Growth

Although vitamin D deficiency has been linked to an increase in cancer incidence, a meta-analysis of 40 randomized controlled trials (RCTs) found that vitamin D supplementation with or without calcium did not reduce skeletal or non-skeletal outcomes in unselected community-dwelling individuals by more than 15%. A randomized controlled study including 14,641 US doctors found that combining vitamin E (400 IU/day) and vitamin C (500 mg/day) supplementation for an average of 10 years had no effect on cancer incidence. Long-term vitamin E (400 IU/day) or selenium (200 g from selenomethionine) supplementation had no influence on the risk of prostate cancer [23].

Changing diet habits may be critical in limiting cancer incidence. Furthermore, it is a safe way for improving patient quality of life without additional risk or potential side effects that occurs from chemotherapy. Furthermore, fasting may play a role in cancer patients clinical outcomes.

According to research, employing a ketogenic diet as an alternative to fasting and calorie restriction has sparked a lot of interest. A ketogenic diet may be better tolerated in certain people, and it has a lengthy track record of safety as an epilepsy therapy. A recent meta-analysis included 12 research that compared an unrestricted ketogenic diet to a regular diet in murine cancer models and concluded that the ketogenic diet resulted in an overall growth delay [28].

Supplementation with long-chain N-3 fatty acids or fish oil was recommended to maintain or increase appetite, food intake, lean body mass, and body weight in patients with advanced cancer receiving chemotherapy with high risk of weight loss or malnutrition [23].

Several anticancer medications are P-glycoprotein (P-gp) substrates; consequently, if P-gp or any cytochrome P450 (CYP) enzyme is affected, the drug it is processing will also be affected. Various herbs and nutritional supplements, such as St. John's wort, are known to impact the pharmacokinetics of various medications. Currently, research on the pharmacokinetic interactions of dietary supplements and cancer drugs is sparse, however there is evidence for numerous probable interactions and adverse responses [32].

Grapefruit and its furanocoumarin components have been researched in vitro and in vivo for their potential antioxidative, anti-inflammatory, and anticancer properties. Grapefruit juice may raise imatinib plasma levels by blocking CYP3A4, resulting in organ damage. On the other hand, after pretreatment with grapefruit

juice, the bioavailability of etoposide (50 mg orally) decreased from roughly 73% to 52%. As etoposide was combined with grapefruit juice, the area under the concentration versus time curve (AUC) decreased by 26% when compared to etoposide alone [32].

Diets high in "plants" (vegetables and fruits), fish, low in alcohol and mammalian fat appear to have a lower cancer incidence than diets low in plants and high in red meat, mammalian fat, and alcohol. Food-related components that have anticancer effect include Plant pigments, pear, basil, thyme, oregano, apple, honeybee propolis, chilli pepper, strawberries, pineapple, coffee, sunflower, blueberries, cinnamon oil, mushroom, garlic, soybean, oats, rice, artichoke, orange, pineapple, peanut, onion, cucumber, black pepper, and broccoli [33].

Cancer Incidence / treatment side effects and Life Style / Habits:

Alcohol intake is responsible for around 4% of all malignancies globally. Drinking alcohol raises the risk of various malignancies, including upper aerodigestive tract, liver, colorectum, and breast cancer [34].

A daily intake of 10 g of alcohol was linked to a 15% higher risk of oral cavity cancer. Cancers of the upper aerodigestive tract are also more than multiplicatively enhanced when alcohol and cigarettes are consumed simultaneously. Several studies have found this synergistic effect; for example, a pooled analysis of 11,200 head and neck cancer cases and 16,200 controls discovered a 14-fold risk of head and neck cancer among those who drank at least three alcoholic drinks per day and smoked more than 20 cigarettes per day, compared to never drinkers who had never smoked [35].

Besides, the "World Cancer Research Fund and American Institute for Cancer Research" meta-analysis discovered a 7% higher risk of colorectal cancer, 7% increased risk of breast cancer (in women), and 14% increased risk of hepatocellular carcinoma every 10 g alcohol consumption per day. On the other hand, non-linear dose-response analysis found an increase in stomach cancer risk for more than 45 g alcohol consumption per day [36].

A clinical study findings indicate that smoking is related with a higher mean total symptom burden (including fatigue, nausea, memory loss, hair loss, depression, sleep problems, pain, difficulty concentrating, weight loss, and skin problems) during treatment, as well as a bigger rise in total symptom burden from before the start of cancer therapy to the greatest severity at any point during treatment. Furthermore, it was showed that six months after therapy, the difference in mean total symptom load between smokers and nonsmokers maintained, with smokers having a considerably higher symptom burden. Smokers reported considerably more attention issues, skin disorders, sleep disturbances, weight loss, and despair [37].

Early cytogenetic investigations demonstrate that heroin use affects and causes considerable alterations in chromosomes. Indeed, research involving neonates of heroin addict moms revealed that

chromosomal abnormalities were six to seven times higher than in the control group of newborns of normal mothers. A study found a link between heroin and carcinogenesis. It specifically demonstrated an unexpected rise in the CNS of M2 protein in individuals with acute myeloid leukaemia, which has previously been linked to heroin addiction [38].

Cocaine usage has been reported to impair responsiveness to chemotherapeutic drugs such as imatinib in patients with chronic myeloid leukaemia, most likely due to cocaine's influence on cytochrome P450 [39].

Cannabis smoking appears to be implicated in carcinogenesis, either as an independent component or in conjunction with other mutagens, according to research data, particularly in studies involving the respiratory and gastrointestinal systems of young adults. However, significant histopathologic and molecular alterations in the bronchial epithelium of chronic hashish users have been reported. More histopathologic lesions were observed in systematic smokers than in the nonsmokers in the control group [38].

6. Conclusion

Dietary intake, certain food products, and fasting regiment have an impact on the gastrointestinal side effects of chemotherapy, tumor growth, and treatment clinical effect in cancer patients. A dietary approach focused on the exclusion or limited intake of specific food products, as well as diet improvement, might minimize and avoid chemotherapy-induced gastrointestinal problems, limit tumor growth and/or incidence. and hence should be considered in clinical practice. Nutritional support showed to reduce in-hospital mortality in cancer patient and improve their quality of life.

References

1. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr*. 2017; 36(1): 11-48.
2. Mitchell T, Clarke L, Goldberg A, Bishop KS. Pancreatic cancer cachexia: the role of nutritional interventions. *Healthcare (Basel)*. 2019; 7(3): 89.
3. Carrato A, Cerezo L, Feliu J, Macarulla T, Martín-Pérez E, Vera R, Álvarez J, Botella-Carretero JI. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. *Clin Transl Oncol*. 2022; 24(1): 112-126.
4. Ghazi T, Arumugam T, Foolchand A, Chuturgoon AA. The Impact of Natural Dietary Compounds and Food-Borne Mycotoxins on DNA Methylation and Cancer. *Cells*. 2020; 9(9): 2004.
5. Mittelman SD. The Role of Diet in Cancer Prevention and Chemotherapy Efficacy. *Annu Rev Nutr*. 2020; 40: 273-97.
6. Hazzard E, Walton K, McMahon AT, Milosavljevic M, Tapsell LC. Healthcare professionals' perspectives on the role of dietitians within multidisciplinary head and neck cancer teams: A qualitative multi-site study. *Nutr Diet*. 2021; 78(5): 506-15.
7. Aktas A, Walsh D, Galang M, O'Donoghue N, Rybicki L, Hullihen B, et al. Underrecognition of Malnutrition in Advanced Cancer: The Role of the Dietitian and Clinical Practice Variations. *Am J Hosp Palliat Care*. 2017; 34(6): 547-55.
8. Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, et al. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol*. 2014; 25(1): 9-15.
9. Boşnak AS, Birand N, Diker Ö, Abdi A, Başgüt B. The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy. *J Oncol Pharm Pract*. 2019; 25(6): 1312-20.
10. Katoue MG. Role of pharmacists in providing parenteral nutrition support: current insights and future directions. *Integr Pharm Res Pract*. 2018; 7: 125-40.
11. Zhao Y, Pang D, Lu Y. The Role of Nurse in the Multidisciplinary Management of Cancer Cachexia. *Asia Pac J Oncol Nurs*. 2021; 8(5): 487-97.
12. Kuo SE, Lai HS, Hsu JM, Yu YC, Zheng DZ, Hou TW. A clinical nutritional information system with personalized nutrition assessment. *Comput Methods Programs Biomed*. 2018; 155: 209-16.
13. Braunschweig CA. Creating a clinical nutrition registry: prospects, problems, and preliminary results. *J Am Diet Assoc*. 1999; 99(4): 467-70.
14. Pedrazzoli P, Caccialanza R, Cotogni P, Degli Esposti L, Perrone V, Sangiorgi D, et al. The Advantages of Clinical Nutrition Use in Oncologic Patients in Italy: Real World Insights. *Healthcare (Basel)*. 2020; 8(2): 125.
15. Kaegi-Braun N, Schuetz P, Mueller B, Kutz A. Association of Nutritional Support With Clinical Outcomes in Malnourished Cancer Patients: A Population-Based Matched Cohort Study. *Front Nutr*. 2021; 7: 603370.
16. Dina KF, Nagwa AS, Amr ST, Sara MS. Evaluation of the clinical effect of pharmacist intervention: Results of patient education about breast cancer. *European Journal of Oncology Pharmacy*. 2020; 3(1): e23.
17. Mardas M, Madry R, Stelmach-Mardas M. Link between diet and chemotherapy related gastrointestinal side effects. *Contemp Oncol (Pozn)*. 2017; 21(2): 162-7.
18. Abdollahi R, Najafi S, Razmpoosh E, Shoormasti RS, Haghight S, Raji Lahiji M, et al. The Effect of Dietary Intervention Along with Nutritional Education on Reducing the Gastrointestinal Side Effects Caused by Chemotherapy Among Women with Breast Cancer. *Nutr Cancer*. 2019; 71(6): 922-30.
19. Calixto-Lima L, Martins de Andrade E, Gomes A, Geller M, Siqueira-Batista R. Dietetic management in gastrointestinal complications from antineoplastic chemotherapy. *Nutr Hosp*. 2012; 27: 65-75.
20. Mardas M, Madry R, Stelmach-Mardas M. Link between diet and chemotherapy related gastrointestinal side effects. *Contemporary Oncology/Współczesna Onkologia*. 2017; 21: 162-7.
21. Alshahawey M, Raslan MA, Sabri NA. COVID-19 and Antiviral

- Therapies in Cancer Patients - will it Make Difference? *Ann Hematol Oncol Res.* 2020; 1(2): 1008.
22. Nagwa A Sabri, et al. Virtual and on Site Vaccination Clinics of COVID-19. Will it be Applicable?. *Acta Scientific Pharmaceutical Sciences.* 2022; 6(1): 141-4.
 23. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. *Clin Nutr.* 2021; 40(5): 2898-913.
 24. Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, et al. Caloric restriction augments radiation efficacy in breast cancer. *Cell Cycle.* 2013; 12: 1955-63
 25. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. *Sci. Transl. Med.* 2012; 4: 124ra27
 26. Bianchi G, Martella R, Ravera S, Marini C, Capitanio S, et al. Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. *Oncotarget.* 2015; 6: 11806-19.
 27. Caffa I, D'Agostino V, Damonte P, Soncini D, Cea M, et al. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. *Oncotarget.* 2015; 6: 11820-32.
 28. Klement RJ, Champ CE, Otto C, Kammerer U. Anti-tumor effects of ketogenic diets in mice: a meta-analysis. *PLOS ONE.* 2016; 11: e0155050.
 29. Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. *PLOS ONE.* 2014; 9:e108444.
 30. Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, et al. 2013. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. *Clin. Cancer Res.* 19: 3905-13.
 31. Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, et al. The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. *PLOS ONE.* 2015; 10: e0130357.
 32. PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Cancer Therapy Interactions With Foods and Dietary Supplements (PDQ®): Health Professional Version. 2022 May 26. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002.
 33. Lefranc F, Tabanca N, Kiss R. Assessing the anticancer effects associated with food products and/or nutraceuticals using in vitro and in vivo preclinical development-related pharmacological tests. *Semin Cancer Biol.* 2017; 46: 14-32.
 34. Rungay H, Shield K, Charvat H, Ferrari P, Sornpaisarn B, Obot I, et al. Global burden of cancer in 2020 attributable to alcohol consumption: A population-based study. *Lancet Oncol.* 2021; 22: 1071-80.
 35. Rungay H, Murphy N, Ferrari P, Soerjomataram I. Alcohol and Cancer: Epidemiology and Biological Mechanisms. *Nutrients.* 2021; 13(9): 3173.
 36. World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective; Continuous Update Project Expert Report; 2018.
 37. Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelins MC, et al. The effect of cigarette smoking on cancer treatment-related side effects. *Oncologist.* 2011; 16(12): 1784-92.
 38. Moussas GI, Papadopoulou AG. Substance abuse and cancer. *Psychiatriki.* 2017; 28(3): 234-41.
 39. Breccia M, Gentilini F, Alimena G. Cocaine abuse may influence the response to imatinib in CML patients. *Haematologica.* 2007; 92: e41-2.